Advancements in autoimmune disease treatment at Monash University

Monash researchers are making significant progress in treating Systemic Lupus Erythematosus (SLE) and other autoimmune diseases:

Associate Professor Sarah Jones and MD-PhD candidate Iolanda Miceli's research on a novel drug targeting strategy for SLE has been recognised by the American College of Rheumatology, with Iolanda receiving the Emerging Investigator Excellence Award.
Associate Professor Joshua Ooi and Professor Richard Kitching have developed 'SMART-regs' to suppress disease-causing immune responses in lupus, with potential applications for other autoimmune diseases.
Monash researchers have advanced treatments focusing on the glucocorticoid-induced leucine zipper (GILZ), leading to the formation of the biotech spinout company GILZ Rx.
The Regulatory T Cell Therapies Group and the Centre for Inflammatory Disease have discovered a method to reprogram defective cells in lupus patients, potentially applicable to other autoimmune diseases.